Breaking News, Financial News

1Q Financial Report: Wyeth

Wyeth

1Q Revenues: $4.8 billion (+6%)

1Q Earnings: $1.1 billion (+13%)

Comments: Enbrel, Effexor, Prevnar, Premarin and Protonix drove revenue growth in the quarter. The company has rights to Enbrel outside of the U.S. and Canada where net revenue was $335 million for the quarter, up 42%. Effexor sales were $945 million, up 9%. Prevnar sales were up 10% to $432 million. Premarin product sales were $266 million for the quarter, up 26%. Protonix sales were $482 million, up 18%. R&D expenses were $684.7 million for the quarter, up +13%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters